IRCT20230330057787N1RecruitingPhase 3
Investigating the prophylactic effect of antiglaucoma drugs on eye pressure in patients undergoing intravitreal injection of bevacizumab
Zahedan University of Medical Sciences0 sites108 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 108
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •1- Age more than 18 years
- •2- Informed and free consent to participate in the study
- •3- Patients who will have the first intra-boasizomat injection.
Exclusion Criteria
- •1- History of retinal surgery.
- •2- Rupture of the posterior capsule
- •3- High eye pressure or glaucoma
- •4- Use of topical medication (such as IOP-lowering medications and corticosteroids)
- •5- Active intraocular inflammation
- •6- Eye pathologies such as pterygium or corneal opacities that can affect the evaluation of study variables
- •7- Withdrawal from the study during research for any reason
Investigators
Similar Trials
Recruiting
Phase 4
Short- and long-term effects of various anti-glaucomatous eye drops on the foveal avascular zone (FAZ)Primary open-angle glaucomaH40.1DRKS00028293Dietrich-Bonhoeffer-KlinikumKlinik für Augenheilkunde200
Completed
Not Applicable
Investigation of the influence of anti-glaucoma eyedrops on corneal stroma and corneal shapeglaucomaJPRN-UMIN000030262Inouye Eye Hospital300
Completed
Not Applicable
Investigation of the influence of anti-glaucoma eyedrops on the ocular surfaceglaucomaJPRN-UMIN000030246Inouye Eye Hospital300
Recruiting
Unknown
Prospective study on efficacy of prophylactic gallbladder stent for preventing acute cholecystitis induced after use of metallic stent placement for malignant biliary stricturesmalignant biliary strictures, bile duct cancer, pancreatic cancer, cholecystitisJPRN-UMIN000050327Sendai City Medical Center100
Not yet recruiting
Phase 2
A study of the effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) for patients with esophageal cancer who receive DCF therapy.esophageal cancerJPRN-UMIN000015561Osaka University School of Medicine Gastroenterological Surgery23